Dyslipidaemia: Balancing the benefits and risks of statin therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Gut microbial alterations and functional shifts in patients with hypertriglyceridemia: insights from a northwestern Chinese metagenomic study.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
   Article
2. Laminarin Reduces Cholesterol Uptake and NPC1L1 Protein Expression in High-Fat Diet (HFD)-Fed Mice.Marine drugs · 2023
   Article
3. Development of New Genome Editing Tools for the Treatment of Hyperlipidemia.Cells · 2023
   Review
4. Statin-induced increase in actin polymerization modulates GPCR dynamics and compartmentalization.Biophysical journal · 2023
   Article
5. The polyphenol-rich extract from chokeberry (Nutrition & metabolism · 2020
   Article

Corrections and comments

• Comment on
  Interpretation of the evidence for the efficacy and safety of statin therapy.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as